Alliance Pharma Regulatory News (APH)

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Pre-Close Trading Update

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces its pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2013.

Trading in the first half of the year has been in line with management's expectations, with turnover of approximately £22.8m (H1 2012: £22.0m).

Turnover increased by 4% despite the unavailability of ImmuCystTM (H1 2012: £1.6m), which is now expected to become available again during the second half of 2014, and the reduction in Nu-SealsTM sales to £1.6m (H1 2012: £2.1m). HydromolTM sales, at £2.6m in the first half (H1 2012: £2.2m), continue to grow well. The antimalarial products acquired in August 2012 contributed £0.8m of sales in the first half, and the stoma care products acquired in October 2012 contributed £2.0m of sales. The first half of 2013 also benefitted from Alliance's toxicology product reaching the peak of its sales cycle.

Alliance continues to explore a number of acquisition opportunities and remains confident of the outlook for the full year.

The Company's interim results for the six months ended 30 June 2013 are scheduled to be released on 11 September 2013.

For further information:

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.